Skip to content Skip to footer
Viewpoints_Richard Watts

Enhancing Diagnostic Care: Richard Watts from Qiagen in a Stimulating Conversation with PharmaShots

Shots: Recently, Qiagen entered into a collaboration agreement with AstraZeneca to develop companion diagnostics for chronic diseases using Qiagen’s QIAstat-Dx system Today, at PharmaShots, we are joined by Richard Watts from Qiagen, who sheds light on their collaboration agreements with AstraZeneca and Eli Lilly, leveraging their syndromic testing platform, QIAstat-Dx Qiagen has partnered with over…

Read more

Eli Lilly

Eli Lilly’s Ebglyss (Lebrikizumab-lbkz) Receives the US FDA’s Approval for Treating Moderate-to-Severe Atopic Dermatitis 

Shots:    The US FDA has approved Ebglyss to treat moderate-to-severe AD in adults & children (≥12yrs.) weighing 88 pounds (40kg). Lilly holds its exclusive rights outside the EU, while Almirall has licensed rights in the EU The approval was supported by P-III (ADvocate 1 & 2) studies of Ebglyss alone and P-III (ADhere) study of…

Read more

Viewpoints_Kasper Roet 

Advancing Neurodegenerative Care: Kasper Roet from QurAlis Corporation in a Stimulating Conversation with PharmaShots

Shots: Recently, QurAlis signed an exclusive license agreement with Lilly for QRL-204 for patients with ALS and FTD Under the terms of the agreement, QurAlis granted Lilly an exclusive worldwide license to develop and commercialize QRL-204 and other UNC13A targeting compounds. QurAlis received an up front payment of $45M plus an additional equity investment. The company is…

Read more

Immunology Top 20 2024

Top 20 Immunology Companies of 2024

Shots:Immunology remains one of the most explored therapy areas. Companies focusing on immunology are steadfastly working to advance treatment options by developing drugs, vaccines, and antibodiesIn 2023, the global immunology market size was valued at $98.22B and expected to register $263.22B by 2033, with a CAGR of 10.36% from 2024 to 2033. AbbVie…

Read more

Eli Lilly

Eli Lilly Reports the US FDA’s Approval of Kisunla (donanemab-azbt) to Treat Early Symptomatic Alzheimer’s Disease 

Shots:  The approval of Kisunla (350mg/20mL, IV, QM) for early symptomatic Alzheimer's disease was based on P-III (TRAILBLAZER-ALZ 2) study. Coverage & reimbursement is available through National Coverage Determination with Coverage with Evidence Development The P-III (TRAILBLAZER-ALZ 2) trial assessed Kisunla vs PBO in patients (n=1,736) with early symptomatic AD (MCI or mild dementia) &…

Read more